Literature DB >> 33669443

Roles of Ceramides in Non-Alcoholic Fatty Liver Disease.

Eric Hajduch1,2, Floriane Lachkar1,2, Pascal Ferré1,2, Fabienne Foufelle1,2.   

Abstract

Non-alcoholic fatty liver disease is one of the most common chronic liver diseases, ranging from simple steatosis to steatohepatitis, fibrosis, and cirrhosis. Its prevalence is rapidly increasing and presently affects around 25% of the general population of Western countries, due to the obesity epidemic. Liver fat accumulation induces the synthesis of specific lipid species and particularly ceramides, a sphingolipid. In turn, ceramides have deleterious effects on hepatic metabolism, a phenomenon called lipotoxicity. We review here the evidence showing the role of ceramides in non-alcoholic fatty liver disease and the mechanisms underlying their effects.

Entities:  

Keywords:  NAFLD; NASH; ceramide; liver; sphingolipids; steatosis

Year:  2021        PMID: 33669443     DOI: 10.3390/jcm10040792

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  10 in total

Review 1.  Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.

Authors:  Sandra Torres; Paula Segalés; Carmen García-Ruiz; José C Fernández-Checa
Journal:  Cells       Date:  2022-04-27       Impact factor: 7.666

2.  Hepatic Unsaturated Fatty Acids Are Linked to Lower Degree of Fibrosis in Non-alcoholic Fatty Liver Disease.

Authors:  Michael Fridén; Fredrik Rosqvist; Håkan Ahlström; Heiko G Niessen; Christian Schultheis; Paul Hockings; Johannes Hulthe; Anders Gummesson; Alkwin Wanders; Fredrik Rorsman; Ulf Risérus; Johan Vessby
Journal:  Front Med (Lausanne)       Date:  2022-01-10

3.  Time-Dependent Changes in Hepatic Sphingolipid Accumulation and PI3K/Akt/mTOR Signaling Pathway in a Rat Model of NAFLD.

Authors:  Klaudia Sztolsztener; Karolina Konstantynowicz-Nowicka; Ewa Harasim-Symbor; Adrian Chabowski
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

4.  Quercetin Reduces Lipid Accumulation in a Cell Model of NAFLD by Inhibiting De Novo Fatty Acid Synthesis through the Acetyl-CoA Carboxylase 1/AMPK/PP2A Axis.

Authors:  Antonio Gnoni; Benedetta Di Chiara Stanca; Laura Giannotti; Gabriele Vincenzo Gnoni; Luisa Siculella; Fabrizio Damiano
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

5.  Lipid metabolism contribute to the pathogenesis of IgA Vasculitis.

Authors:  Ying Liu; Min Wen; Qingnan He; Xiqiang Dang; Shipin Feng; Taohua Liu; Xuewei Ding; Xiaoyan Li; Xiaojie He
Journal:  Diagn Pathol       Date:  2022-02-11       Impact factor: 2.644

6.  Lipidomics Revealed Alteration of the Sphingolipid Metabolism in the Liver of Nonalcoholic Steatohepatitis Mice Treated with Scoparone.

Authors:  Qi Song; Hu Liu; Yunqi Zhang; Chuanqi Qiao; Shaoqin Ge
Journal:  ACS Omega       Date:  2022-04-14

7.  Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection.

Authors:  Marcus Höring; Georg Peschel; Jonathan Grimm; Sabrina Krautbauer; Martina Müller; Kilian Weigand; Gerhard Liebisch; Christa Buechler
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

8.  FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.

Authors:  Marie O'Farrell; Greg Duke; Richard Crowley; Douglas Buckley; Eduardo B Martins; Dipankar Bhattacharya; Scott L Friedman; George Kemble
Journal:  Sci Rep       Date:  2022-09-19       Impact factor: 4.996

Review 9.  Metabolic-associated fatty liver disease and lipoprotein metabolism.

Authors:  Joerg Heeren; Ludger Scheja
Journal:  Mol Metab       Date:  2021-04-20       Impact factor: 7.422

10.  Role of sphingosine kinase and sphingosine-1-phosphate receptor in the liver pathology of mice infected with Plasmodium berghei ANKA.

Authors:  Tachpon Techarang; Pitchanee Jariyapong; Chuchard Punsawad
Journal:  PLoS One       Date:  2022-03-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.